<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Shukla R</submitter><funding>NIAID NIH HHS</funding><funding>Dutch Research Council (NWO)</funding><pubmed_abstract>Antimicrobial resistance is a leading mortality factor worldwide. Here we report the discovery of clovibactin, a new antibiotic, isolated from uncultured soil bacteria. Clovibactin efficiently kills drug-resistant bacterial pathogens without detectable resistance. Using biochemical assays, solid-state NMR, and atomic force microscopy, we dissect its mode of action. Clovibactin blocks cell wall synthesis by targeting pyrophosphate of multiple essential peptidoglycan precursors (C &lt;sub>55&lt;/sub> PP, Lipid II, Lipid &lt;sub>WTA&lt;/sub> ). Clovibactin uses an unusual hydrophobic interface to tightly wrap around pyrophosphate, but bypasses the variable structural elements of precursors, accounting for the lack of resistance. Selective and efficient target binding is achieved by the irreversible seque</pubmed_abstract><journal>bioRxiv : the preprint server for biology</journal><pagination>2023.05.15.540765</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10245560</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A new antibiotic from an uncultured bacterium binds to an immutable target.</pubmed_title><pmcid>PMC10245560</pmcid><funding_grant_id>711.018.001</funding_grant_id><funding_grant_id>R01 AI170962</funding_grant_id><funding_grant_id>R43 AI091224</funding_grant_id><funding_grant_id>184.032.207</funding_grant_id><funding_grant_id>R44 AI091224</funding_grant_id><funding_grant_id>R43 AI136137</funding_grant_id><funding_grant_id>P01 AI118687</funding_grant_id><funding_grant_id>R44 AI136137</funding_grant_id><funding_grant_id>723.014.003</funding_grant_id><pubmed_authors>Honorato RV</pubmed_authors><pubmed_authors>Ling LL</pubmed_authors><pubmed_authors>Kubitscheck U</pubmed_authors><pubmed_authors>Lelli M</pubmed_authors><pubmed_authors>Krueger AM</pubmed_authors><pubmed_authors>Vermeulen BJA</pubmed_authors><pubmed_authors>Spoering AL</pubmed_authors><pubmed_authors>Achorn C</pubmed_authors><pubmed_authors>de Benedetti S</pubmed_authors><pubmed_authors>Hughes D</pubmed_authors><pubmed_authors>Schwalen CJ</pubmed_authors><pubmed_authors>Lewis K</pubmed_authors><pubmed_authors>Lavore F</pubmed_authors><pubmed_authors>Nitti A</pubmed_authors><pubmed_authors>Schneider T</pubmed_authors><pubmed_authors>Grein F</pubmed_authors><pubmed_authors>Derks MGN</pubmed_authors><pubmed_authors>Maity S</pubmed_authors><pubmed_authors>Roos WH</pubmed_authors><pubmed_authors>Breukink E</pubmed_authors><pubmed_authors>Ludwig KC</pubmed_authors><pubmed_authors>Weingarth M</pubmed_authors><pubmed_authors>Shukla R</pubmed_authors><pubmed_authors>Peoples AJ</pubmed_authors><pubmed_authors>Bonvin A</pubmed_authors></additional><is_claimable>false</is_claimable><name>A new antibiotic from an uncultured bacterium binds to an immutable target.</name><description>Antimicrobial resistance is a leading mortality factor worldwide. Here we report the discovery of clovibactin, a new antibiotic, isolated from uncultured soil bacteria. Clovibactin efficiently kills drug-resistant bacterial pathogens without detectable resistance. Using biochemical assays, solid-state NMR, and atomic force microscopy, we dissect its mode of action. Clovibactin blocks cell wall synthesis by targeting pyrophosphate of multiple essential peptidoglycan precursors (C &lt;sub>55&lt;/sub> PP, Lipid II, Lipid &lt;sub>WTA&lt;/sub> ). Clovibactin uses an unusual hydrophobic interface to tightly wrap around pyrophosphate, but bypasses the variable structural elements of precursors, accounting for the lack of resistance. Selective and efficient target binding is achieved by the irreversible seque</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2025-04-21T14:40:26.971Z</modification><creation>2025-04-21T14:40:26.971Z</creation></dates><accession>S-EPMC10245560</accession><cross_references><pubmed>37292624</pubmed><doi>10.1101/2023.05.15.540765</doi></cross_references></HashMap>